简介:AIM:Toassesstheeffectivenessofimmunosuppressantsintheprophylaxisofcornealallograftrejectionafterhigh-riskkeratoplastyandnormal-riskkeratoplasty.METHODS:WesearchedtheCochraneCentralRegisterofControlledTrials(CENTRAL),MEDLINE,EMBASE,CNKI,VIPandreferencelistsofarticles.Dateofmostrecentsearch:18June,2011.Allrandomisedcontrolledtrials(RCTs)assessingtheuseofimmunosupressantsinthepreventionofgraftrejection,irrespectiveofpublicationlanguage.Twoauthorsassessedtrialqualityandextracteddataindependently.Onlydichotomousoutcomes(cleargraftsurvival,ratioofimmunereactionsandsideeffects)wereavailableandwereexpressedasrelativerisk(RR)and95%confidenceintervals(CI).RESULTS:Sevenstudieswereincludedinthisreview.Inthecomparingofmycophenolatemofetil(MMF)withplacebo,theresultsshowedMMFcouldsignificantlyreduceimmunereactionscomparedwithplacebo(RR1.0895%Cl0.95to1.21),butnoeffectoncleargraftsurvival(RR1.1195%Cl0.90to1.35).Incleargraftsurvivalandimmunereactions,MMFandcyclosporineA(CsA)showedsimilareffect(RR1.1195%Cl0.90to1.35,andRR1.48,95%Cl0.56to3.93,respectively).Tacrolimus(FK506)andsteroidshowedsimilareffectsoncleargraftsurvivalandimmunereactions(RR0.32,95%CI0.02to6.21,andRR1.00,95%CI0.88to1.14,respectively).Nodrugrelativesideeffecthasbeenfound.CONCLUSION:MMFmayreduceimmunereactionsinbothnormal-riskandhigh-riskrejectionofpenetratingkeratoplasty.CsAandFK506showedsimilareffectsasMMF.However,duetothelackoflargeclinicaltrials,theevidenceremainweak,thequalityofevidenceswereratedasverylowtomoderate.Large,properlyrandomised,placebo-controlled,doublemaskedtrialsareneededtoevaluatetheeffectofimmunosuppressants.
简介:AIM:Tocomparetheeffectoftopicallyadministeredandsubconjunctivallyinjectedbevacizumabonexperimentalcornealneovascularizationinratsfortwoweeksaftertreatment.METHODS:Twenty-eightSprague-Dawleyratsweredividedintofourgroupsof7animals.Eachcornealcenterofrighteyewascauterizedwithsilver/potassiumnitratefor8s.Aftercornealburning,bevacizumab(12.5mg/mL)wastopicallyadministeredthreetimesperday(TBgroup)fortwoweeksorsubconjunctivallyinjectedondays2and4aftercauterization(0.02mL;SBgroup).Asnegativecontrols,ratsreceived0.9%salinetopicallythreetimesperday(TSgroup)orsubconjunctivallyondays2and4(0.02mL;SSgroup).Digitalphotographsofthecorneaweretaken1and2weeksaftertreatmentandanalyzedtodeterminetheareaofcorneacoveredbyneovascularizationasthepercentageofcornealneovascularization.RESULTS:Oneweekaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBandSBgroupsthanintheTSandSSgroups(allP<0.05).Twoweeksaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBgroupthanintheTSgroup(P<0.05).Inallgroups,thepercentageofneovascularizationwasdecreasingastimepassed(allP<0.05)CONCLUSION:Topicallyadministeredbevacizumabhaslongerstandinganti-angiogeniceffectthansubconjunctivallyinjectedbevacizumabincornealneovascularizationfollowingchemicalinjuryinrats.
简介:目的:分析抗血管内皮生长因子(VEGF)药物加Ahmed青光眼引流阀(AGV)对新生血管性青光眼(NVG)的疗效和安全性。方法:选取2020.01-2020.11本院收治的NVG患者10例为研究对象,均通过抗VEGF药物加AGV开展治疗,观察术后不同时间的手术成功率;术前及术后不同时间的眼压水平、视力改变、视功能受损眼病患者生活质量评定量表(QOL)评分和并发症情况。结果:术后1d及1周,手术成功率达到100.00%,后伴随时间延长有轻微下降,但术后不同时间的手术成功率相比无显著差异(P>0.05)。术后1d及1周,眼压水平较术前显著下降(P<0.05),至术后1个月眼压有轻度升高,但仍低于术前(P<0.05),术前及术后眼压水平相比差异显著(P<0.05)。术后1d及1周,视力提升比例达到100.00%,术后1个月开始有轻微下降,但术后不同时间的视力水平相比无显著差异(P>0.05)。术后,患者QOL评分术前显著升高(P<0.05),至术后1个月QOL评分有轻度下降,但仍高于术前(P<0.05)。10例患者中1例出现前房少量出血,1例出现轻度角膜水肿,均未经特殊处理后自行消失,无1例出现严重并发症。结论:抗VEGF加AGV对NVG患者疗效确切,能改善其视力,降低其眼压水平,且安全性较高,值得采用。
简介:目的探讨前列腺素类药结合玻璃体腔注射雷珠单抗治疗新生血管性青光眼的效果。方法伴发高眼压的新生血管性青光眼患者160例根据随机数字表法分为治疗组80例与对照组80例,两组都给予复合式小梁切除术,对照组选择拉坦前列腺素辅助治疗,治疗组选择拉坦前列腺素联合玻璃体腔注射雷珠单抗辅助治疗。结果治疗后治疗组与对照组的治疗有效率分别为97.5%和88.8%,治疗组的治疗有效率明显高于对照组(P〈0.05)。两组治疗后最佳矫正视力都明显提高,而眼压都明显下降,与治疗前对比差异明显(P〈0.05);同时治疗后治疗组的最佳矫正视力与眼压也都明显好于对照组(P〈0.05)。治疗期间治疗组的眼结膜充血、前房炎症反应、角膜水肿、一过性视觉模糊等并发症发生率都明显低于对照组(P〈0.05)。所有患者治疗后随访调查6个月,治疗组的治疗后3个月与6个月的复发率分别为1.3%和5.0%,而对照组分别为7.5%和13.8%,治疗组治疗后3个月与6个月的复发率明显少于对照组(P〈0.05)。结论前列腺素类药结合玻璃体腔注射雷珠单抗治疗新生血管性青光眼能促进眼压的降低,改善视力水平,安全性好,降低复发,从而有利于近远期疗效的提高。
简介:目的探讨电话回访、微信等方式对闭角型青光眼患者出院后进行延伸护理服务,以提高患者遵医行为和改善护患关系的影响。方法将160例闭角型青光眼患者随机分为对照组和观察组各80例,对观察组患者于出院后第一周开始电话回访,以后分别于两周、一月、三月、六月、一年回访。对照组采用常规方法。一年后对2组患者遵医行为和再入院人数及满意度进行评价。结果观察组患者在随访期间遵医行为人数及满意度调查,明显好于对照组,再入院人数明显少于对照组(P〈0.01)。结论延伸护理服务有利于患者掌握闭角型青光眼相关的健康教育知识,增强患者遵医行为,调动患者的主观能动性,对延缓病情进展、预防并发症、减少再入院次数、减轻经济负担、提高生活质量起到了促进作用。
简介:目的探讨运用示教与反示教在年龄相关性白内障患者滴眼药护理中的效果。方法将100例患者随机分为实验组和对照组各50例,对照组采用传统的健康教育。实验组采用示教与反示教进行健康教育。由培训过的责任护士对患者有计划地从入院到出院,给予全程、个体化的示教与反示教健康教育。结果实验组患者在滴眼药知识、技能掌握及对护理工作满意度方面优于对照组,差异有统计学意义(P0.05),术后一周并发症的发生率明显低于对照组(P〈O.05)。结论运用示教与反示教对患者实施健康教育,可达到提高患者滴眼药的技能,自我效能感增加,遵医行为增强,自护能力提高,减少术后并发症,提高护理满意度。
简介:AIM:ToinvestigatetheexpressionsoftypeIcollagen,α2integrinandβ1integrinintheposteriorscleraofguineapigswithdefocusmyopiaandwhetherbasicfibroblastgrowthfactor(bFGF)injectioninhibitstheformationanddevelopmentofmyopiabyupregulatingtheexpressionoftypeIcollagen,α2integrinandβ1integrin.METHODS:After14daysoftreatment,therefractivestateandaxiallengthweremeasuredandthelevelsoftypeIcollagen,α2integrinandβ1integrinwereassayedintheposteriorscleraeofgroupsofguineapigsthatworeamonocular-7Dpolymethylmethacrylate(PMMA)lensorhad-7DlenswearfollowedbytheperibulbarinjectionofPhosphateBufferSolution(PBS)orbFGF.Theuntreatedfelloweyeservedasacontrol.Guineapigswithnotreatmentservedasnormalgroup.·RESULTS:Theresultsshowedthat14daysofmonoculardefocusincreasedaxialeyelengthandrefraction,whilebFGFdeliveryinhibitedthemmarkedly.Further,itwasalsofoundthatthemonocular-7DlenscoulddecreasethelevelsoftypeIcollagen,α2integrinandβ1integrinexpressions,while,unlikePBS,bFGFincreasedthemsignificantlyincomparisontocontralateralcontroleyesandnormaleyes.CONCLUSION:bFGFcanpreventtheformationanddevelopmentofdefocusmyopiabyupregulatingtheexpressionsoftypeIcollagen,α2integrinandβ1integrin.Takentogether,ourresultsdemonstratethatbFGFpromotesscleraremodelingtopreventmyopiainguineapigs.
简介:目的探讨玻璃体腔注射雷珠单抗辅助23G玻璃体切割治疗增殖期糖尿病视网膜病变的优质护理。方法通过对28例28眼采用玻璃体腔注射雷珠单抗辅助玻璃体切割治疗糖尿病患者并发视网膜增殖期病变存在的主要护理问题,针对患者治疗各阶段,责任护士提供全程、连续、系统的优质护理服务,加强护患沟通,提高护理质量,缩短手术时间,减少并发症的发生。结果24眼一次性手术复位成功(85.7%)术后三个月取出硅油,其中有4例伴有晶状体混浊的同时行晶状体超声乳化联合人工晶体植入术;4例硅油填充下仍然存在下方局限性视网膜增殖,术后三个月取出硅油再次切割增殖膜然后注入C3F8气体填充,随访至气体完全吸收,视网膜复位。结论对玻璃体腔注射雷珠单抗辅助23G玻璃体切割治疗增殖期糖尿病视网膜病变的患者提供优质护理,可缩短手术时间,减少并发症的发生,提高病人及家属的满意度,提升患者的康复效果,是手术取得成功的关键因素。
简介:AIM:ToInvestigatetheeffectsoftransforminggrowthfactorβ2(TGF-β2)andconnectivetissuegrowthfactor(CTGF)ontransdifferentiationofhumanlensepithelialcells(HLECs)culturedinvitroandsynthesisofextracellularmatrix(ECM).METHODS:HLECsweretreatedwithTGF-β2(0,0.5,1.0,5,10μg/L)andCTGF(0,15,30,60,100μg/L)fordifferenttimes(0,24,48,72h)invitroandtheexpressionofα-smoothmuscleactin(α-SMA),themaincomponentoftheextracellularmatrixtypeⅠcollagen(Col-1)andfibronectin(Fn)weremeasuredbyusingreal-timepolymerasechainreaction(PCR)andwestern-blot.RESULTS:TGF-β2andCTGFsignificantlyincreasedexpressionofα-SMAmRNAandprotein(P<0.05,P<0.001),FnmRNAandprotein(P<0.001),Col-1mRNAandprotein(P<0.001).TGF-β2couldinduceHLECsexpressionofCTGFmRNAandproteinindosedependentmanner(P<0.05,P<0.001).TGF-β2andCTGFcouldinduceHLECstoexpressα-SMA,FnandCol-1intime-dependentmanner.EachtimeofTGF-β2andCTGFinducedHELCsexpressionofα-SMA,Fn,Col-1mRNAandproteinwassignificantincreasecomparedwithcontrol(P<0.05,P<0.001).CONCLUSION:TGF-β2andCTGFcouldinduceHLECsepithelialmesenchymaltransitionandECMsynthesis.